SG11201701648UA - Use of cysteamine in treating infections caused by yeasts/moulds - Google Patents
Use of cysteamine in treating infections caused by yeasts/mouldsInfo
- Publication number
- SG11201701648UA SG11201701648UA SG11201701648UA SG11201701648UA SG11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA SG 11201701648U A SG11201701648U A SG 11201701648UA
- Authority
- SG
- Singapore
- Prior art keywords
- cysteamine
- yeasts
- moulds
- infections caused
- treating infections
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 229960003151 mercaptamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053523P | 2014-09-22 | 2014-09-22 | |
| GBGB1416727.4A GB201416727D0 (en) | 2014-09-22 | 2014-09-22 | Use |
| PCT/GB2015/052714 WO2016046524A1 (en) | 2014-09-22 | 2015-09-21 | Use of cysteamine in treating infections caused by yeasts/moulds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701648UA true SG11201701648UA (en) | 2017-04-27 |
Family
ID=51869299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701648UA SG11201701648UA (en) | 2014-09-22 | 2015-09-21 | Use of cysteamine in treating infections caused by yeasts/moulds |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3197476A1 (zh) |
| JP (1) | JP2017532317A (zh) |
| KR (1) | KR20170052613A (zh) |
| CN (1) | CN106687140A (zh) |
| AU (1) | AU2015323566B2 (zh) |
| BR (1) | BR112017005272A2 (zh) |
| CA (1) | CA2959003A1 (zh) |
| GB (1) | GB201416727D0 (zh) |
| MX (1) | MX2017003550A (zh) |
| NZ (1) | NZ730092A (zh) |
| RU (1) | RU2017108196A (zh) |
| SG (1) | SG11201701648UA (zh) |
| WO (1) | WO2016046524A1 (zh) |
| ZA (1) | ZA201701330B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991099A1 (en) | 2015-07-02 | 2017-01-05 | Horizon Orphan Llc | Ado-resistant cysteamine analogs and uses thereof |
| WO2018140594A1 (en) * | 2017-01-25 | 2018-08-02 | Adare Pharmaceuticals, Inc. | Cysteamine prodrugs |
| WO2018224813A1 (en) * | 2017-06-06 | 2018-12-13 | Novabiotics Limited | Use of cysteamine compositions |
| CA3116637A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| CN110551637B (zh) * | 2019-09-03 | 2020-11-27 | 黑龙江省农业科学院植物保护研究所 | 一种来自黄芪根部的高效抑制番茄灰霉病菌的棘壳孢菌及其应用 |
| CN110859950B (zh) * | 2019-11-25 | 2021-08-10 | 武汉大学 | 一种用于白念珠菌棘白菌素类药物耐药菌的药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696164A (en) * | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US6086921A (en) * | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
| PL1778720T3 (pl) * | 2004-08-18 | 2011-03-31 | Novabiotics Ltd | Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę |
| JP2006347990A (ja) * | 2005-06-20 | 2006-12-28 | Pola Chem Ind Inc | 爪用の抗真菌医薬組成物 |
| JP2006347989A (ja) * | 2005-06-20 | 2006-12-28 | Pola Chem Ind Inc | 爪用の抗真菌医薬組成物 |
| GB0905451D0 (en) * | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| SG177750A1 (en) * | 2009-08-13 | 2012-03-29 | Moberg Derma Ab | Compositions and methods for treating fungal infection of the nail |
| GB201021186D0 (en) * | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
-
2014
- 2014-09-22 GB GBGB1416727.4A patent/GB201416727D0/en not_active Ceased
-
2015
- 2015-09-21 SG SG11201701648UA patent/SG11201701648UA/en unknown
- 2015-09-21 EP EP15770619.3A patent/EP3197476A1/en not_active Withdrawn
- 2015-09-21 MX MX2017003550A patent/MX2017003550A/es unknown
- 2015-09-21 KR KR1020177008807A patent/KR20170052613A/ko unknown
- 2015-09-21 AU AU2015323566A patent/AU2015323566B2/en not_active Ceased
- 2015-09-21 WO PCT/GB2015/052714 patent/WO2016046524A1/en active Application Filing
- 2015-09-21 JP JP2017515704A patent/JP2017532317A/ja active Pending
- 2015-09-21 BR BR112017005272A patent/BR112017005272A2/pt not_active Application Discontinuation
- 2015-09-21 RU RU2017108196A patent/RU2017108196A/ru not_active Application Discontinuation
- 2015-09-21 CA CA2959003A patent/CA2959003A1/en not_active Abandoned
- 2015-09-21 CN CN201580051064.7A patent/CN106687140A/zh active Pending
- 2015-09-21 NZ NZ730092A patent/NZ730092A/en not_active IP Right Cessation
-
2017
- 2017-02-22 ZA ZA2017/01330A patent/ZA201701330B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170052613A (ko) | 2017-05-12 |
| RU2017108196A3 (zh) | 2019-06-19 |
| CN106687140A (zh) | 2017-05-17 |
| JP2017532317A (ja) | 2017-11-02 |
| GB201416727D0 (en) | 2014-11-05 |
| NZ730092A (en) | 2018-05-25 |
| MX2017003550A (es) | 2017-07-28 |
| BR112017005272A2 (pt) | 2017-12-12 |
| CA2959003A1 (en) | 2016-03-31 |
| EP3197476A1 (en) | 2017-08-02 |
| AU2015323566B2 (en) | 2018-03-22 |
| ZA201701330B (en) | 2018-04-25 |
| RU2017108196A (ru) | 2018-10-24 |
| AU2015323566A1 (en) | 2017-04-06 |
| WO2016046524A1 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of multiple sclerosis complex | |
| HRP20192119T8 (hr) | Pripravak i metoda za pomoć pri spavanju | |
| PT2923823T (pt) | Corpo moldado e processo para o seu fabrico | |
| SG11201702688UA (en) | Methods of treating rsv infections | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| ZA201701330B (en) | Use of cysteamine in treating infections caused by yeasts / moulds | |
| GB201416006D0 (en) | Organotypic skin model | |
| GB201416102D0 (en) | Impovements In or Relating To Shower Rods | |
| HK1225994A1 (zh) | 用於治療過敏性病症的組合物 | |
| ZA201608607B (en) | Novel fluoroquinolones and use thereof to treat bacterial infections | |
| GB201405013D0 (en) | Improvements in or relating to manufacture of packaging | |
| IL249152A0 (en) | Botulinum toxin for use in the treatment of paratonia | |
| IL249616A0 (en) | Methods for treating inflammation | |
| IL251040A0 (en) | Using cysteamine to treat infections caused by yeasts/molds | |
| GB202013077D0 (en) | Improvements in and relating to servo valves | |
| PT3160263T (pt) | Composições para prevenção de infeções | |
| ZA201801788B (en) | Lysobactin for use in the treatment of bovine mastitis | |
| GB201521802D0 (en) | Mould treatment | |
| GB201410990D0 (en) | General cure to diseases |